Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2017

Share Based Compensation Option And Incentive Plan [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity for the nine months ended September 30, 2017 and 2016:

					Weighted-Average
	Number of		Weighted- Average		Contractual Life
	Options		Exercise Price		(In Years)
Outstanding at December 31, 2016		1,509,711	$	2.85		5.04
Granted		482,950		1.44		9.60
Exercised		(61,078)		0.67
Expired		(73,283)		2.19
Outstanding at September 30, 2017		1,858,300	$	2.62		5.61
Exercisable at September 30, 2017		1,188,317	$	2.68		4.56
Vested and Expected to Vest at September 30, 2017		1,188,317	$	2.68		4.56

Outstanding at December 31, 2015		1,277,367	$	2.75		4.94
Granted		355,071		2.81		9.50
Exercised		(86,765)		0.65
Forfeited		(12,362)		3.93
Outstanding at September 30, 2016		1,533,311	$	2.91		6.44
Exercisable at September 30, 2016		907,445	$	2.84		4.09
Vested and Expected to Vest at September 30, 2016		907,445	$	2.84		4.09

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

For the nine months ended September 30, 2017 and 2016, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:

	2017	2016
Risk-Free Interest Rate	1.82%	1.82%
Expected Life	7.28 years	7.00 years
Expected Volatility	171%	65%
Expected Dividend Yield	0%	0%

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Research and Development	$	57,544	$	17,092	$	165,538	$	35,692
General and Administrative		131,148		135,973		535,295		354,777
	$	188,692	$	153,065	$	700,833	$	390,469